Visbiome GI Care: De Simone Formulation, Pouchitis Evidence & Strains

Visbiome GI Care is a probiotic medical food built around the De Simone Formulation. One capsule contains 112.5 billion CFU, and the manufacturer identifies all eight organisms with strain designations.

That formulation identity matters because the cited pouchitis evidence applies to the formulation studied, not simply to products with similar species lists or legacy brand names.

The eight-strain formulation

The current Visbiome strain information identifies the De Simone Formulation as a defined combination of eight lactobacilli, bifidobacteria and Streptococcus thermophilus, with DSM/SD strain identifiers.

The product requires refrigeration at 36–46°F and is shipped under cold-chain conditions. The manufacturer states potency is guaranteed through the best-by date when stored as directed.

Pouchitis guidance and formulation identity

The American Gastroenterological Association’s guideline on pouchitis suggests probiotics for prevention of recurrent pouchitis in people who respond to antibiotics. The recommendation is conditional and the evidence is low certainty.

The guideline’s implementation discussion notes that the De Simone Formulation was used in the prevention trials it reviewed.

This links the formulation to a specific clinical scenario. It does not establish that every person with a J-pouch should use Visbiome, and treatment decisions for recurrent pouchitis belong in gastroenterology care.

Legacy VSL#3 naming

Older studies frequently used the name VSL#3 for the De Simone Formulation. A Cochrane review cautions that the formulation historically tested under that name is now marketed in the United States as Visbiome, while the current product sold as VSL#3 is a different formulation.

Following the formulation name is therefore important when interpreting older studies.

Evidence that should not be generalized

The pouchitis evidence does not establish efficacy for:

• undiagnosed bloating;
• routine IBS treatment;
• general “microbiome balance”;
• immune enhancement;
• replacing standard therapy for inflammatory bowel disease.

Those uses require their own evidence.

Main tradeoff

The product discloses a defined eight-strain formulation and has a direct evidence connection to a specific pouchitis scenario. The guideline recommendation is conditional, based on low-certainty evidence and relevant to medically supervised care rather than generic wellness use.

For routine probiotic shopping, return to the probiotics evidence guide rather than choosing by CFU count alone.